Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension

被引:162
作者
Leuchte, HH [1 ]
Neurohr, C [1 ]
Baumgartner, R [1 ]
Holzapfel, M [1 ]
Giehrl, W [1 ]
Vogeser, M [1 ]
Behr, J [1 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med, Div Pulm Dis, D-81377 Munich, Germany
关键词
natriuretic peptide; brain; hypertension; pulmonary; fibrosis;
D O I
10.1164/rccm.200308-1142OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Pulmonary hypertension (PH) can develop in lung fibrosis, and contributes to increased morbidity and mortality. Noninvasive parameters in the evaluation of PH in lung disease could aid in the management of these subjects. In this study, we aimed to characterize the role of brain natriuretic peptide (BNP) and the six-minute walk distance (6-MWD) in the assessment of pulmonary hypertension (PH) in subjects with lung fibrosis. Subjects with lung fibrosis and elevated BNP levels (n = 20) had significantly more severe PH during right heart catheterization than those with lung fibrosis, and normal BNP levels (mean pulmonary arterial pressure (40.85 +/- 3.2 mm Hg vs. 23.42 +/- 1.44 mm Hg, respectively) (n = 19) (p < 0.001). Significant correlations between lung volumes and BNP concentrations were not observed. A weak correlation existed between capillary pO(2) and 6-MWD (r = 0.42; p < 0.001). The presence of moderate-severe PH was associated with significant reduction of the 6-MWD. BNP concentrations predicted moderate-severe PH with 100% sensitivity and high specificity (89%). We conclude that BNP is an excellent marker for the presence of PH in patients with lung fibrosis. In addition, our data suggest that PH contributes significantly to exercise limitation in patients with severe lung fibrosis, raising the possibility that treatment of PH may be beneficial in these patients.
引用
收藏
页码:360 / 365
页数:6
相关论文
共 43 条
[1]  
[Anonymous], 1999, Am J Respir Crit Care Med, V160, P736
[2]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00
[3]   Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease [J].
Arcasoy, SM ;
Christie, JD ;
Ferrari, VA ;
Sutton, MS ;
Zisman, DA ;
Blumenthal, NP ;
Pochettino, A ;
Kotloff, RM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) :735-740
[4]   Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation [J].
Arcasoy, SM ;
Christie, JD ;
Pochettino, A ;
Rosengard, BR ;
Blumenthal, NP ;
Bavaria, JE ;
Kotloff, RM .
CHEST, 2001, 120 (03) :873-880
[5]  
Aris R, 1998, AM J RESP CRIT CARE, V158, P335
[6]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[7]   Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale [J].
Bando, M ;
Ishii, Y ;
Sugiyama, Y ;
Kitamura, S .
RESPIRATORY MEDICINE, 1999, 93 (07) :507-514
[8]   SYSTEMIC LUPUS-ERYTHEMATOSUS - EMERGING CONCEPTS .1. RENAL, NEUROPSYCHIATRIC, CARDIOVASCULAR, PULMONARY, AND HEMATOLOGIC DISEASE [J].
BOUMPAS, DT ;
AUSTIN, HA ;
FESSLER, BJ ;
BALOW, JE ;
KLIPPEL, JH ;
LOCKSHIN, MD .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (12) :940-950
[9]  
Bourke SJ, 2001, EUR RESPIR J, V18, p81S
[10]   Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea [J].
Cabanes, L ;
Richaud-Thiriez, B ;
Fulla, Y ;
Heloire, F ;
Vuillemard, C ;
Weber, S ;
Dusser, D .
CHEST, 2001, 120 (06) :2047-2050